专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US5190973A 20-alkyl-7-oxoprostacyclin derivatives useful as pharmaceuticals 失效
标题翻译：可用作药物的20-烷基-7-氧代前列环素衍生物
公开(公告)号：US5190973A
公开(公告)日：1993-03-02
申请号：US599916
申请日：1990-10-19
申请人： Robert Nickolson , Helmut Vorbrueggen , Claus S. Stuerzebecher , Martin Haberey
发明人： Robert Nickolson , Helmut Vorbrueggen , Claus S. Stuerzebecher , Martin Haberey
IPC分类号： C07C405/00 , C07D307/935 , C07D307/937
CPC分类号： C07D307/935 , C07C405/00 , C07D307/937
摘要： The invention concerns 20-alkyl-7-oxoprostacyclin derivatives of general Formula I ##STR1## wherein R.sub.1 is the residue OR.sub.3 where R.sub.3 means hydrogen or alkyl of 1-10 carbon atoms optionally substituted by halogen, phenyl, C.sub.1 -C.sub.4 -alkoxy or C.sub.1 -C.sub.4 -dialkylamino; cycloalkyl, aryl or a heterocyclic residue, or the residue NHR.sub.4 where R.sub.4 means hydrogen or an alkanoyl or alkanesulfonyl residue of respectively 1-10 carbon atoms,n is 1 or 2,A is a CH.sub.2 --CH.sub.2 --, cis--CH.dbd.CH-- or trans--CH.dbd.CH--group,W is a ##STR2## or a ##STR3## wherein the OH-group can respectively be esterified with a benzoyl or alkanoic acid residue of 1-4 carbon atoms, or etherified with a tetrahydropyranol, tetrahydrofuranyl, alkoxyalkyl or trialkylsilyl residue, wherein the free or esterified OH-group can be in the .alpha.- or .beta.-position,R.sub.2 is a straight-chain or branched-chain alkyl group of 1-6 carbon atoms,R.sub.5 is a hydroxy group which can be esterified with an alkanoic acid residue of 1-4 carbon atoms or etherified with a tetrahydropyranyl, tetrahydrofuranyl, alkoxyalkyl or trialkylsilyl residue,R.sub.6 and R.sub.7 are hydrogen or a straight-chain or branched-chain alkyl group of 1-4 carbon atoms, or R.sub.6 and R.sub.7 jointly represent a trimethylene group,R.sub.8 and R.sub.9 jointly represent a linkage or hydrogen or a straight-chain or branched-chain alkyl group of 1-4 carbon atoms,and, if R.sub.3 is hydrogen, the salts thereof with physiologically compatible bases; their production; and their use as medicinal agents.
摘要翻译：本发明涉及通式I（I）的20-烷基-7-氧代前列环素衍生物，其中R 1是残基OR 3，其中R 3表示氢或1-10个碳原子的任选被卤素，苯基，C 1 -C 4 - 烷氧基或C 1 -C 4 - 二烷基氨基; 环烷基，芳基或杂环残基，或残基NHR4，其中R4表示氢或分别为1-10个碳原子的烷酰基或烷磺酰基，n为1或2，A为CH2-CH2-，顺式-CH = CH- 或反式-CH = CH-基团，W为“IMAGE”或“IMAGE”，其中OH基团可分别用1-4个碳原子的苯甲酰基或链烷酸残基酯化，或用四氢吡喃醇醚化，四氢呋喃基，烷氧基烷基或三烷基甲硅烷基残基，其中游离或酯化的OH基可以是α或β-位，R2是1-6个碳原子的直链或支链烷基，R5是羟基，可以用1-4个碳原子的链烷酸残基酯化，或与四氢吡喃基，四氢呋喃基，烷氧基烷基或三烷基甲硅烷基残基醚化，R6和R7是氢或1-4个碳原子的直链或支链烷基，或R6和R7共同表示三亚甲基，R8和R9共同表示键或氢或1-4个碳原子的直链或支链烷基，如果R 3是氢，则其与生理上相容的碱的盐; 他们的生产; 并将其用作药剂。

2. 发明授权

US4532236A Certain prostacyclins and their blood-pressure-lowering and thrombocyte-aggregation-inhibiting compositions and methods 失效
公开(公告)号：US4532236A
公开(公告)日：1985-07-30
申请号：US531898
申请日：1983-07-27
申请人： Robert Nickolson , Helmut Vorbrueggen , Jorge Casals-Stenzel , Martin Haberey
发明人： Robert Nickolson , Helmut Vorbrueggen , Jorge Casals-Stenzel , Martin Haberey
IPC分类号： A61K31/34 , A61K31/557 , A61P43/00 , C07C51/09 , C07C51/38 , C07C55/32 , C07C57/52 , C07C69/533 , C07C69/593 , C07C69/65 , C07C405/00 , C07D307/935 , C07D307/937 , C07D407/00 , C07D407/12 , C07F7/18 , C07F9/40
CPC分类号： C07D307/935 , C07C405/00 , C07C405/0033 , C07C51/09 , C07C51/38 , C07C55/32 , C07C57/52 , C07D307/937 , C07D407/12 , C07F7/1856 , C07F9/4015
摘要： Prostacyclin derivatives of general Formula I ##STR1## wherein R.sub.1 is the residue OR.sub.3 wherein R.sub.3 means hydrogen or alkyl of 1-10 carbon atoms substituted, if desired, by halogen, aryl, C.sub.1 -C.sub.4 -alkoxy, or C.sub.1 -C.sub.4 -dialkylamino; cycloalkyl, aryl, or a heterocyclic residue; or is the residue NHR.sub.4 wherein R.sub.4 means hydrogen, an alkanoyl residue, or an alkanesulfonyl residue of respectively 1-10 carbon atoms,A is a --CH.sub.2 --CH.sub.2 -- or trans--CH.dbd.CH--group,W is a ##STR2## wherein the OH-group can be respectively esterified with a benzoyl or alkanoic acid residue of 1-4 carbon atoms, or can be etherified with a tetrahydropyranyl, tetrahydrofuranyl, C.sub.1 -C.sub.4 -alkoxyalkyl, or tri(C.sub.1 -C.sub.4 -alkyl)-silyl residue, wherein the free or esterified OH-group can be in the .alpha.- or .beta.-position,D and E jointly mean a direct bond orD is a straight-chain or branched alkylene group of 1-5 carbon atoms,E is an oxygen atom or a direct bond,R.sub.2 is a straight-chain or branched-chain alkyl group of 1-6 carbon atoms, a straight-chain or branched-chain alkenyl group of 2-6 carbon atoms which can be substituted by phenyl, halogen, or C.sub.1 -C.sub.4 -alkyl and, if D and E jointly represent a direct bond, is an alkynyl residue of 2-6 carbon atoms optionally substituted in the 1-position by halogen or C.sub.1 -C.sub.4 -alkyl,R.sub.5 is a hydroxy group which can be esterified with an alkanoic acid residue of 1-4 carbon atoms or which can be etherified with a tetrahydropyranyl, tetrahydrofuranyl, alkoxyalkyl, or trialkylsilyl residue and, if R.sub.3 is hydrogen, the salts thereof with physiologically compatible bases, and a process for the preparation thereof.The compounds exhibit blood-pressure-lowering and thrombocyte-aggregation-inhibiting activity.

3. 发明授权

US4721729A Novel carbacyclins, process for the preparation thereof, and their use as medicinal agents 失效
标题翻译：新型碳环霉素，其制备方法及其作为药剂的用途
公开(公告)号：US4721729A
公开(公告)日：1988-01-26
申请号：US702092
申请日：1985-02-08
申请人： Werner Skuballa , Bernd Raduechel , Helmut Vorbrueggen , Robert Nickolson , Martin Haberey , Olaf Loge , Claus-Steffen Stuerzebecher
发明人： Werner Skuballa , Bernd Raduechel , Helmut Vorbrueggen , Robert Nickolson , Martin Haberey , Olaf Loge , Claus-Steffen Stuerzebecher
IPC分类号： C07C43/14 , A61K31/557 , A61P43/00 , C07C27/00 , C07C35/31 , C07C35/52 , C07C41/00 , C07C45/00 , C07C49/24 , C07C49/255 , C07C49/76 , C07C67/00 , C07C405/00 , C07C177/00
CPC分类号： C07C405/0083 , Y10S514/829
摘要： Carbacyclins of Formula I ##STR1## wherein R.sub.1 is an alkyl, cycloalkyl, aryl, aralkyl, or heterocyclic group,Y is a keto group or a hydroxymethylene group,X is a --CH.sub.2 -- group or an oxygen atom,A is a --CH.sub.2 --CH.sub.2 --, a trans--CH.dbd.CH-- or a --C.tbd.C-- group,W is a hydroxymethylene group or a ##STR2## D is the group ##STR3## a straight-chain or branched, saturated alkylene group or unsaturated alkylene group of up to 5 carbon atoms which can optionally be substituted by 1-2 fluorine atoms,n is 1, 2 or 3,E is a direct bond, a --C.tbd.C-- group or a --CR.sub.4 .dbd.CR.sub.5 -- group wherein R.sub.4 is hydrogen or an alkyl group and R.sub.5 is hydrogen, halogen or an alkyl group,R.sub.2 is an alkyl, cycloalkyl, aryl, or heterocyclic group, andR.sub.3 is a hydroxy group,are valuable, e.g., as cytoprotective agents.
摘要翻译：式I的卡巴菌素其中R 1是烷基，环烷基，芳基，芳烷基或杂环基，Y是酮基或羟亚甲基，X是-CH 2 - 基或氧原子，A是 -CH 2 -CH 2 - ，反式-CH = CH-或-C 3 C C基团，W是羟基亚甲基基团，或者D是基团，即直链或支链饱和亚烷基或至多5个碳原子的不饱和亚烷基，其可任选被1-2个氟原子取代，n为1,2或3，E为直接键，-C 3位C基团或-CR 4 = CR 5 - 基团，其中R 4是氢或烷基，R 5是氢，卤素或烷基，R 2是烷基，环烷基，芳基或杂环基，并且R 3是羟基，是有价值的，例如作为细胞保护剂。

4. 发明授权

US5013758A Novel carbacyclins, processes for their preparation and their use as medicinal agents 失效
标题翻译：新型碳霉素，其制备方法及其用作药物
公开(公告)号：US5013758A
公开(公告)日：1991-05-07
申请号：US434561
申请日：1989-11-13
申请人： Werner Skuballa , Bernd Raduechel , Helmut Vorbrueggen , Claus-Steffen Stuerzebecher , Martin Haberey , Ekkehard Schillinger , Michael H. Town
发明人： Werner Skuballa , Bernd Raduechel , Helmut Vorbrueggen , Claus-Steffen Stuerzebecher , Martin Haberey , Ekkehard Schillinger , Michael H. Town
IPC分类号： A61K31/557 , A61P9/12 , C07C51/00 , C07C51/367 , C07C59/125 , C07C67/00 , C07C405/00 , C07D309/12
CPC分类号： C07C405/0083 , C07D309/12
摘要： (5E)-13,14,18,18,19,19-hexadehydro-3-oxa-6a-carbaprostaglandin I.sub.2 derivatives of Formula I ##STR1## wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4 are hydrogen or alkyl of 1-5 carbon atoms, andR.sub.5 is an alkyl group of 1-5 carbon atoms, as well as the physiologically compatible salts thereof;have pharmacologically valuable activity.
摘要翻译：（I）的（5E）-13,14,18,18,19,19-六氢-3-氧杂-10-碳前列腺素I 2衍生物其中R 1，R 2，R 3，R 4为氢或烷基， -5个碳原子，R5是1-5个碳原子的烷基，以及其生理上相容的盐; 具有药理学有价值的活动。

5. 发明授权

US07459470B2 N-oxide anthranylamide derivatives and their use as medicaments 失效
标题翻译： N-氧化物苯甲酰胺衍生物及其作为药物的用途
公开(公告)号：US07459470B2
公开(公告)日：2008-12-02
申请号：US10476755
申请日：2002-05-03
申请人： Alexander Ernst , Andreas Huth , Martin Krueger , Karl-Heniz Thierauch , Andreas Menrad , Martin Haberey
发明人： Alexander Ernst , Andreas Huth , Martin Krueger , Karl-Heniz Thierauch , Andreas Menrad , Martin Haberey
IPC分类号： A61K31/47 , C07D213/89
CPC分类号： C07D213/89 , C07D401/12 , C07D405/12
摘要： Substituted N-oxidanthranilamide derivatives, their production and use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis are described. The compounds according to the invention can be used as or in the case of psoriasis, Kaposi's sarcoma, restenosis, endometriosis, Crohn's disease, Hodgkin's disease, leukemia; arthritis, such as rheumatoid arthritis, hemangioma, angiofibroma; eye diseases, such as diabetic retinopathy, neovascular glaucoma; renal diseases, such as glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombic microangiopathic syndrome, transplant rejections and glomerulopathy; fibrotic diseases, such as cirrhosis of the liver, mesangial cell proliferative diseases, arteriosclerosis, injuries to nerve tissue, and inhibition of the reocclusion of vessels after balloon catheter treatment, in vascular prosthetics or after mechanical devices are used to keep vessels open, such as, e.g., stents, as immunosuppressive agents, as a support in scar-free healing, senile keratosis and contact dermatitis. The compounds according to the invention can also be used as VEGFR-3 inhibitors in the case of lymphangiogenesis.
摘要翻译：描述了取代的N-氧化邻氨基苯甲酰胺衍生物，其作为用于治疗由持续性血管生成触发的疾病的药剂的生产和用途被描述。根据本发明的化合物可以用作银屑病，卡波西肉瘤，再狭窄，子宫内膜异位症，克罗恩病，霍奇金病，白血病，牛皮癣，关节炎，如类风湿关节炎，血管瘤，血管纤维瘤; 眼睛疾病如糖尿病性视网膜病变，新生血管性青光眼; 肾脏疾病如肾小球性肾炎，糖尿病肾病，恶性肾硬化，血栓性微血管病综合征，移植排斥反应和肾小球病; 纤维化疾病，如肝硬化，肾小球膜细胞增生性疾病，动脉硬化，神经组织损伤，以及球囊导管治疗后血管再狭窄的抑制，血管修复术或机械装置用于保持血管开放的诸如例如作为免疫抑制剂的支架，作为无疤痕愈合的支持，老年角化病和接触性皮炎。在淋巴管生成的情况下，根据本发明的化合物也可以用作VEGFR-3抑制剂。

6. 发明申请

US20060116380A1 Novel anthranilamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors 失效
公开(公告)号：US20060116380A1
公开(公告)日：2006-06-01
申请号：US11265517
申请日：2005-11-03
申请人： Rolf Bohlmann , Martin Haberey , Andreas Huth , Stuart Ince , Martin Krueger , Karl-Heinz Thierauch , Holger Hess-Stumpp , Andreas Reichel
发明人： Rolf Bohlmann , Martin Haberey , Andreas Huth , Stuart Ince , Martin Krueger , Karl-Heinz Thierauch , Holger Hess-Stumpp , Andreas Reichel
IPC分类号： A61K31/506 , A61K31/501 , A61K31/4709 , A61K31/497 , A61K31/444 , C07D403/14 , C07D401/14
CPC分类号： C07D401/12
摘要： The invention relates to novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors, their production and use as pharmaceutical agents for preventing or treating diseases that are triggered by persistent angiogenesis.

7. 发明授权

US07012081B2 Anthranyl amides and their use as medicaments 失效
标题翻译：氨基酰胺和它们作为药物的用途
公开(公告)号：US07012081B2
公开(公告)日：2006-03-14
申请号：US10275479
申请日：2001-05-07
申请人： Martin Krueger , Andreas Huth , Orlin Petrov , Dieter Seidelmann , Karl-Heinz Thierauch , Martin Haberey , Andreas Menrad , Alexander Ernst
发明人： Martin Krueger , Andreas Huth , Orlin Petrov , Dieter Seidelmann , Karl-Heinz Thierauch , Martin Haberey , Andreas Menrad , Alexander Ernst
IPC分类号： A61K31/47 , C07D215/00 , C07D217/00
CPC分类号： C07D213/80 , C07C237/40 , C07D211/26 , C07D211/32 , C07D211/62 , C07D217/22 , C07D265/26 , C07D309/04 , C07D309/06 , C07D317/72 , C07D401/12 , C07D405/12
摘要： Substituted anthranilamides and use thereof as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis as well as their intermediate products for the production of anthranilamides are described.
摘要翻译：描述了取代的邻氨基苯甲酰胺及其用作治疗由持续血管发生引起的疾病的药物及其用于制备邻氨基苯甲酰胺的中间产物。

8. 发明授权

US06878720B2 VEGF receptor tyrosine kinase inhibitors 失效
标题翻译： VEGF受体酪氨酸激酶抑制剂
公开(公告)号：US06878720B2
公开(公告)日：2005-04-12
申请号：US10180289
申请日：2002-06-26
申请人： Karl-Heinz Altmann , Guido Bold , Pascal Furet , Paul William Manley , Jeanette Marjorie Wood , Stefano Ferrari , Francesco Hofmann , Jürgen Mestan , Andreas Huth , Martin Krüger , Dieter Seidelmann , Andreas Menrad , Martin Haberey , Karl-Heinz Thierauch
发明人： Karl-Heinz Altmann , Guido Bold , Pascal Furet , Paul William Manley , Jeanette Marjorie Wood , Stefano Ferrari , Francesco Hofmann , Jürgen Mestan , Andreas Huth , Martin Krüger , Dieter Seidelmann , Andreas Menrad , Martin Haberey , Karl-Heinz Thierauch
IPC分类号： C07D233/64 , A61K20060101 , A61K31/00 , A61K31/166 , A61K31/167 , A61K31/415 , A61K31/417 , A61K31/44 , A61K31/4409 , A61K31/443 , A61K31/444 , A61K31/47 , A61K31/4745 , A61K31/497 , A61K31/505 , A61P20060101 , A61P17/00 , A61P27/02 , A61P35/00 , A61P43/00 , C07C20060101 , C07C223/02 , C07C237/30 , C07C317/26 , C07D20060101 , C07D211/22 , C07D213/04 , C07D213/38 , C07D213/40 , C07D213/61 , C07D213/64 , C07D213/89 , C07D215/12 , C07D215/14 , C07D215/36 , C07D215/58 , C07D233/54 , C07D265/26 , C07D401/12 , C07D401/14 , C07D405/12 , C07D407/12 , C07D409/12 , C07D413/12 , C07D471/02
CPC分类号： A61K31/415 , A61K31/44 , A61K31/47 , C07D213/38 , C07D213/56 , C07D213/64 , C07D213/89 , C07D215/12 , C07D233/54 , C07D405/12
摘要： Described are compunds of formula (I), wherein W is O or S; X is NR8; Y is CR9R10—(CH2)n wherein R9 and R10 are independently of each other hydrogen or lower alkyl, and n is an integer of from and including 0 to and including 3; or Y is SO2; R1 is aryl; R2 is a bicyclic heteroaryl group comprising one ring nitrogen atom with the exception that R2 cannot represent 2-phthalimidyl; any of R3, R4, R5 and R6, independently of the other, is H or a substituent other than hydrogen; and R7 and R8, independently of each other, are H or lower alkyl; or a N-oxide or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical product for the treatment of a neoplastic disease which responds to an inhibition of the VEGF receptor tyrosine kinase activity. The compounds of formula (I) can be used for the treatment e.g. of a neoplastic disease, such as a tumor disease, of retinopathy and age-related macular degeneration.
摘要翻译：描述的是式（I）的化合物，其中W是O或S; X为NR8; Y为CR 9 R 10 - （CH 2）n，其中R 9和R 10彼此独立地为氢或低级烷基，n为0〜3的整数。或Y为SO2; R1是芳基; R2是包含一个环氮原子的二环杂芳基，不同的是R 2不能代表2-邻苯二酰亚氨基; R 3，R 4，R 5和R 6中的任何一个独立地为H或氢以外的取代基; 且R 7和R 8彼此独立地为H或低级烷基; 或N-氧化物或其药学上可接受的盐在制备用于治疗对VEGF受体酪氨酸激酶活性的抑制作出反应的肿瘤疾病的药物产品中的用途。式（I）化合物可用于治疗，例如，的肿瘤疾病，如肿瘤疾病，视网膜病变和年龄相关性黄斑变性。

9. 发明申请

US20050054654A1 VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines 失效
标题翻译： VEGFR-2和VEGFR-3抑制性邻氨基苯甲酰胺吡啶
公开(公告)号：US20050054654A1
公开(公告)日：2005-03-10
申请号：US10870491
申请日：2004-06-18
申请人： Andreas Huth , Ludwig Zorn , Martin Krueger , Stuart Ince , Karl Thierauch , Andreas Menrad , Martin Haberey , Holger Hess-Stumpp
发明人： Andreas Huth , Ludwig Zorn , Martin Krueger , Stuart Ince , Karl Thierauch , Andreas Menrad , Martin Haberey , Holger Hess-Stumpp
IPC分类号： C07D213/61 , C07D213/73 , C07D213/74 , C07D213/75 , C07D401/04 , C07D401/12 , C07D401/14 , C07D409/12 , C07D413/04 , C07D413/14 , C07D417/04 , C07D43/02 , A61K31/497 , A61K31/501 , A61K31/506 , C07D41/02
CPC分类号： C07D213/61 , C07D213/73 , C07D213/74 , C07D213/75 , C07D401/04 , C07D401/12 , C07D401/14 , C07D409/12 , C07D413/04 , C07D413/14 , C07D417/04
摘要： VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridinamides, their production and use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis, as well as intermediate products for the production of the compounds are described. The compounds according to the invention can be used as or in the case of tumor or metastasis growth, psoriasis, Kaposi's sarcoma, restenosis, such as, e.g., stent-induced restenosis, endometriosis, Crohn's disease, Hodgkin's disease, leukemia; arthritis, such as rheumatoid arthritis, hemangioma, angiofibroma; eye diseases, such as diabetic retinopathy, neovascular glaucoma; renal diseases, such as glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombic microangiopathic syndrome, transplant rejections and glomerulopathy; fibrotic diseases, such as cirrhosis of the liver; mesangial cell proliferative diseases, arteriosclerosis, injuries to nerve tissue, and inhibition of the reocclusion of vessels after balloon catheter treatment, in vascular prosthetics or after mechanical devices are used to keep vessels open, such as, e.g., stents, as immunosuppressive agents, as a support in scar-free healing, senile keratosis and contact dermatitis. The compounds according to the invention can also be used as VEGFR-3 inhibitors in the case of lymphangiogenesis.
摘要翻译：描述了VEGFR-2和VEGFR-3抑制性邻氨基苯酰胺吡啶酰胺，其作为用于治疗由持续血管发生引起的疾病的药物的制备和用途，以及用于制备化合物的中间产物。根据本发明的化合物可用于或在肿瘤或转移生长的情况下，牛皮癣，卡波西肉瘤，再狭窄，例如支架诱导的再狭窄，子宫内膜异位，克罗恩病，霍奇金病，白血病; 关节炎，如类风湿关节炎，血管瘤，血管纤维瘤; 眼睛疾病如糖尿病性视网膜病变，新生血管性青光眼; 肾脏疾病如肾小球性肾炎，糖尿病肾病，恶性肾硬化，血栓性微血管病综合征，移植排斥反应和肾小球病; 纤维化疾病，如肝硬化; 肾小球膜细胞增生性疾病，动脉硬化，神经组织损伤，以及球囊导管治疗后血管假体中或使用机械装置用于保持血管开放（例如，支架）作为免疫抑制剂的抑制，作为免疫抑制剂无疤痕愈合，老年角化病和接触性皮炎的支持。在淋巴管生成的情况下，根据本发明的化合物也可以用作VEGFR-3抑制剂。

10. 发明授权

US06376480B1 Vitamin D derivatives with substituents at C-25, process for their production, intermediate products and use for the production of pharmaceutical agents 失效
标题翻译： C-25具有取代基的维生素D衍生物，其制备方法，中间产物和用于生产药剂的用途
公开(公告)号：US06376480B1
公开(公告)日：2002-04-23
申请号：US09738286
申请日：2000-12-18
申请人： Gerald Kirsch , Andreas Steinmeyer , Günter Neef , Katica Schwarz , Ruth Thieroff-Ekerdt , Herbert Wiesinger , Andreas Menrad , Martin Haberey
发明人： Gerald Kirsch , Andreas Steinmeyer , Günter Neef , Katica Schwarz , Ruth Thieroff-Ekerdt , Herbert Wiesinger , Andreas Menrad , Martin Haberey
IPC分类号： A61K3159
CPC分类号： C07C401/00
摘要： A method of preparing a pharmaceutical composition, comprising combining a pharmaceutically compatible vehicle with a compound according to formula (I)
摘要翻译：一种制备药物组合物的方法，包括将药学上相容的载体与式（I）化合物

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式